Your Invitation to Attend:

Personalized Medicine for Neuropsychiatric Disorders

AN ASSUREX HEALTH PRESENTATION

Genesight: Improving Mental Wellness in Long Term Care

Thursday, September 10, 2015
006:00pm - 08:00pm EST

PRESENTER

Lucas Watterson, PhD

Medical Science Liaison
Assurex Health

LOCATION

Harvest Seasonal Grill

1460 Bethlehem Pike
North Wales, PA
267-460-8986

TO REGISTER

Kevin A. Carbaugh

Assurex Health
kcarbaugh@assurerxhealth.com
717-278-6621

RSVP

By 09/3/2015

Dinner will be provided.

Lucas Watterson, PhD

Dr. Watterson received his PhD in psychology with a focus in behavioral neuroscience from Arizona State University and completed post-doctoral training at the Center for Substance Abuse Research (CSAR) at the Temple University School of Medicine. At both ASU and CSAR, his research employed rodent behavioral models to 1) evaluate the abuse liability of novel "legal high" designer stimulants. 2) investigate the effects of chronic stimulant abuse on cognitive functioning, and 3) assess various glutamatergic ligands as potential anti-relapse pharmacotherapeutics for psychostimulant addiction. Dr. Watterson has published 21 peer-reviewed articles including 13 original research articles, 5 review articles, and 3 book chapters. In addition to research, Dr. Watterson has also taught numerous classes at both the undergraduate and postgraduate levels.

GeneSight® analyzes how a patient's genes may affect his/her metabolism and response to FDA-approved medicines commonly prescribed to treat neuropsychiatric disorders and chronic pain. The information from the GeneSight test can help clinicians select the medication(s) and dose(s) that are better suited to a patient's condition and genetic makeup. GeneSight can provide an objective and personalized approach to treatment. Four published clinical studies verify the efficacy and utility of GeneSight. Patients whose treatment was guided by GeneSight experienced a 70% greater reduction in depressive symptoms compared to treatment as usual.[1] The GeneSight pharmacogenomic test is developed in the Assurex Health clinical laboratory and is based on patented technology licensed from two world renowned medical centers, Mayo Clinic and Cincinnati Children's Hospital Medical Center, who continue to be research collaborators. In clinical use for more than 5 years, GeneSight has over 8,000 registered healthcare providers and over 80,000 patients who have undergone GeneSight testing.

assurex health | 6030 S. Mason-Montgomery Road
Mason, OH 45040
866.260.2394

genesight®

www.genesight.com

©2014 AssureRx Health, Inc.
Assurex Health is a DBA of AssureRx Health, Inc.
Assurex and GeneSight are trademarks of AssureRx Health, Inc.
All rights reserved. Printed in the U.S.A.

1. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS, Eisterhold LL, Geske J, Mrazek DA. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and Genomics. 2013;23(10):535-548.